Metolazone-loaded solid lipid nanoparticle: Preparation and characterization

Year 2025, Volume: 29 Issue: 6, 2218 - 2229, 02.11.2025

Mohammad Faizan Shaikh Aakib Shaikh Aejaz Ahemad Gulam Javed Khan

https://doi.org/10.12991/jrespharm.1796208

Abstract

The Metolazone is a diuretic used in the treatment of hypertension and edema. However, its poor aqueous solubility limits its bioavailability and therapeutic efficacy. This study aims to prepare solid lipid nanoparticles (SLNs) loaded with metolazone using an emulsification and low-temperature solidification method and to enhance the solubility and bioavailability of Metolazone through improved formulation techniques. The SLNs were prepared using glyceryl monostearate (GMS) as the lipid matrix, Poloxamer as the surfactant, and lecithin as a stabilizer. The solid lipid nanoparticles (SLNs) were characterized by a particle size, polydispersity index PDI, entrapment efficiency and zeta potential. Characterization of the SLNs included determination of particle size 189.7 nm, polydispersity index PDI of 0.2, high entrapment efficiency 98.26% and zeta potential -21.52 mV. In this study, metolazone–loaded solid lipid nanoparticles were successfully prepared and characterized. Also the bioavailability of Metolazone, a drug with inherently low solubility when administered orally were significantly enhanced.

Keywords

Solid lipid nanoparticles , bioavailability , solubility , pre-formulation studies

References

• [1] Enna SJ, Bylund DB (Editors), XPharm: The comprehensive pharmacology reference. Elsevier, 2008, pp.9690.
• [2] Procaccini DE, Sawyer JE, Watt KM. Pharmacology of Cardiovascular Drugs. In: Ungerleider RM, Meliones JN, McMillan KN, Cooper DS, Jacobs JP (editors). Critical Heart Disease in Infants and Children. 3rd ed. Elsevier, 2019, pp. 192-212. https://doi.org/10.1016/C2010-0-68865-1
• [3] Enna SJ, Bylund DB (Editors), XPharm: The comprehensive pharmacology reference. Elsevier, 2008, pp.9690-9693.
• [4] Ekambaram P, Sathali AAH, Priyanka K. Solid Lipid Nanoparticles: A Review. Sci Rev Chem Commun. 2012; 2(1): 80-120. https://doi.org/10.1080/13543776.2020.1720649
• [5] López KL, Ravasio A, González-Aramundiz JV, Zacconi FC. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) prepared by microwave and ultrasound-assisted synthesis: Promising green strategies for the nanoworld. Pharmaceutics. 2023;15(5):1333. https://doi.org/10.3390/pharmaceutics15051333
• [6] Nemati S, Mottaghi M, Karami P, Mirjalali H. Development of solid lipid nanoparticles-loaded drugs in parasitic diseases. Discov Nano. 2024;19(1):7. https://doi.org/10.1186/s11671-023-03955-w
• [7] Tzachev CT, Svilenov HL. Lipid nanoparticles at the current stage and prospects – A review article. Int J Pharm Sci Rev Res. 2013;18(1):103-115.
• [8] Taylor JM, Scale K, Arrowsmith S, Sharp A, Flynn S, Rannard S, McDonald TO. Using pyrene to probe the effects of poloxamer stabilizers on internal lipid microenvironments in solid lipid nanoparticles. Nanoscale Adv. 2020;2(12):5572-5577. https://doi.org/10.1039/D0NA00582G
• [9] Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, Kolimi P, Nyavanandi D, Dyawanapelly S. Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles. Pharmaceutics. 2022;14(9):1886. https://doi.org/10.3390/pharmaceutics14091886
• [10] Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin12. Eur J Pharm Sci. 2009;37(4):508-513. https://doi.org/10.1016/j.ejps.2009.04.008
• [11] Duong VA, Nguyen TT, Maeng HJ. Preparation of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Drug Delivery and the Effects of Preparation Parameters of Solvent Injection Method. Molecules. 2020;25(20):4781. https://doi.org/10.3390/molecules25204781
• [12] Doppalapudi S, Suryadevara V. Preparation and evaluation of metolazone solid dispersions and fast dissolving tablets using Sterculia foetida seed starch and Plasdone K-29/32 as superdisintegrants. Int J Appl Pharm. 2020;12(4):144-151. https://doi:10.22159/ijap.2020v12i4.37975
• [13] Prasad BD, Kanth BC, Vasanthi R, Mohan MR, Prabhakar D. A validated UV spectroscopic method of metolazone in bulk and its tablet dosage forms. Int J Biol Pharm Res. 2012;3(1):154-157.
• [14] Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2018. 8th ed. Vol. 2. Ghaziabad: Indian Pharmacopoeia Commission; 2018. p. 2581-2583.
• [15] Creteanu A, Lisa G, Vasile C, Popescu MC, Spac AF, Tantaru G. Development of Solid Lipid Nanoparticles for Controlled Amiodarone Delivery. Methods Protoc. 2023;6(5):97. https://doi.org/10.3390/mps6050097
• [16] Akbari J, Saeedi M, Morteza-Semnani K, Rostamkalaei SS, Asadi M, Asare-Addo K, Nokhodchi A. The design of naproxen solid lipid nanoparticles to target skin layers. Colloids Surf B Biointerfaces. 2016;145:626-633. https://doi: 10.1016/j.colsurfb.2016.05.064.
• [17] Yu JY, Kim JA, Joung HJ, Ko JA, Park HJ. Preparation and characterization of curcumin solid dispersion using HPMC. J Food Sci. 2020;85(11):3866-3873. https://doi.org/10.1111/1750-3841.15489
• [18] Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chem Pharm Bull (Tokyo). 2010;58(5):650-655. https://doi.org/10.1248/cpb.58.650
• [19] Prajapati AP, Upadhyay H, Patel B, Luhar S, Narkhede S. Formulation development and evaluation of solid lipid nanoparticles for the antihypertensive chlorthalidone drug. Int J Food Nutr Sci. 2012;11(1):2320-7876.
• [20] Khatak S, Mehta M, Awasthi R, Paudel KR, Singh SK, Gulati M, Hansbro NG, Hansbro PM, Dua K, Dureja H. Solid lipid nanoparticles containing anti-tubercular drugs attenuate the Mycobacterium marinum infection. Tuberculosis (Edinb). 2020;125:102008. https://doi.org/10.1016/j.tube.2020.102008
• [21] Amekyeh H, Billa N. Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil. Molecules. 2021;26(4):908. https://doi.org/10.3390/molecules26040908
• [22] Bhattacharya S, Sharma S. Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability, in-vivo activity, histopathology, and immunohistochemistry. Front Oncol. 2023;13:1102269. https://doi.org/10.3389/fonc.2023.1102269 [23] Devi RA, Vidyavathi M. Donepezil hydrochloride loaded solid lipid nanoparticles: Formulation, in vitro–in vivo pharmacokinetic and pharmacodynamics evaluation. Int J Appl Pharm. 2022;14(3):125-134.
• [24] Gulati P, Dewangan HK. Aceclofenac loaded solid lipid nanoparticles: optimization, in vitro and ex-vivo evaluation. Int J Appl Pharm. 2023;15(4):184-190. https://doi.org/10.22159/ijap.2023v15i4.48047
• [25] Iquba MK, Iquba A, Imtiyaz K, Rizvi MMA, Gupta MM, Ali J, Baboota S. Combinatorial lipid-nanosystem for dermal delivery of 5-fluorouracil and resveratrol against skin cancer: Delineation of improved dermatokinetics and epidermal drug deposition enhancement analysis. Eur J Pharm Biopharm. 2021;163:223-239. https://doi.org/10.1016/j.ejpb.2021.04.007
• [26] Hajwani A, Khan A, Ansari N, Zerdi N, Baig MS. Fabrication of Transdermal gel embedded with solid lipid nanoparticles of ındomethacin. Int J Drug Deliv Technol. 2023;13(1):414-4172.
• [27] Nagaraj B, Tirumalesh C, Dinesh S, Narendar D. Zotepine loaded lipid nanoparticles for oral delivery: development, characterization, and in vivo pharmacokinetic studies. Futur J Pharm Sci. 2020;6:37. https://doi.org/10.1186/s43094-020-00051-z
• [28] Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm. 2015;41(12):1968-1977. https://doi.org/10.3109/03639045.2015.1024685